Drug
Zenagamtide clinical trials
Also written NNC0487-0111.
- studies test it
- 26
- open now
- 21
- in phase 3
- 15
- first study started
- 2023
Keep track of what changes. Save the zenagamtide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
25 studies that test it; most in 2026 (21); 1 more planned to start later
| Year | Studies |
|---|---|
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 21 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 1
- Phase 3
- 15
What it is tested for
Each study’s main condition, where its own words name it.
- Obesity
- 22
Who runs them
Industry 26 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses zenagamtide is read from its arms, and is right about nine times in ten.
Testing it · 26
- A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide MedicationRecruitingPhase 1Novo Nordisk A/SNCT07855133Written as Zenagamtide
- A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide MedicationRecruitingPhase 1Novo Nordisk A/SNCT07868354Written as Zenagamtide
- AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaRecruitingPhase 3Novo Nordisk A/SNCT07571109Written as NNC0487-0111
- A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With Overweight or ObesityRecruitingPhase 1Novo Nordisk A/SNCT07815067Written as Zenagamtide injection
- A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or ObesityNot yet recruitingPhase 3Novo Nordisk A/SNCT07861100Written as Zenagamtide
- A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Overweight or Obesity, Compared to a Low-calorie Diet or PlaceboRecruitingPhase 1Novo Nordisk A/SNCT07757087Written as NNC0487-0111
- AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightRecruitingPhase 3Novo Nordisk A/SNCT07533175Written as NNC0487-0111
- A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to SemaglutideRecruitingPhase 3Novo Nordisk A/SNCT07668414Written as Zenagamtide
- AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose WeightRecruitingPhase 3Novo Nordisk A/SNCT07720271Written as zenagamtide
- AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose WeightRecruitingPhase 3Novo Nordisk A/SNCT07339423Written as NNC0487-0111
- AMAZE 10: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People in Japan With Excess Body Weight Lose WeightRecruitingPhase 3Novo Nordisk A/SNCT07822061Written as NNC0487-0111
- AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaRecruitingPhase 3Novo Nordisk A/SNCT07571005Written as NNC0487-0111
- AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes MedicationsRecruitingPhase 3Novo Nordisk A/SNCT07797335Written as Zenagamtide
- AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose WeightNot yet recruitingPhase 3Novo Nordisk A/SNCT07668401Written as Zenagamtide
- A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityRecruitingPhase 3Novo Nordisk A/SNCT07567001Written as NNC0487-0111
- AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainRecruitingPhase 3Novo Nordisk A/SNCT07509307Written as NNC0487-0111
- A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainRecruitingPhase 3Novo Nordisk A/SNCT07481630Written as NNC0487-0111
- A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in People With Reduced Liver Function and Normal Liver FunctionNot yet recruitingPhase 1Novo Nordisk A/SNCT07587710Written as NNC0487-0111
- A Research Study Looking at How NNC0487-0111 Affects Food Intake, Appetite and Metabolism After Meals in People With ObesityRecruitingPhase 1Novo Nordisk A/SNCT07508020Written as NNC0487-0111
- Investigating How NNC0487-0111 Regulates Insulin of Adults With Type 2 DiabetesRecruitingPhase 1Novo Nordisk A/SNCT07535307Written as NNC0487-0111
Codes
What other systems call zenagamtide · ClinicalTrials.gg INT017962
- UNII (FDA) T2EA5S9XJ5ZENAGAMTIDEOne source FDA
- NCI Thesaurus C224807ZenagamtideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | T2EA5S9XJ5 | ZENAGAMTIDE | One source FDA |
| NCI Thesaurus | C224807 | Zenagamtide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.